History and prior care
The clinician reviews the clinical question, medical history and treatments already considered.
Additional care / Evidence-aware reviewSelected discussions.
Selected discussions.
Clear limitations.
Low-dose naltrexone may be discussed for selected patients after an individual evaluation. It is not first-line for every concern or a routine component of testosterone or peptide care.
A considered approach01 02 03
Evidence, medications and alternatives.
Medication review
Opioid use and other medicines are essential to the safety discussion; no self-directed combination is recommended.
A defined reassessment
The plan includes a clinician-selected follow-up rather than an assumed long-term prescription.
Capsule formatCare option
Low-dose naltrexone.
A separate, evidence-aware prescribing conversation. Current medications and indication-specific risks are part of the evaluation.
Compounded low-dose naltrexone is not FDA-approved. Evidence is limited and indication-specific. It must not be combined with opioids, including some pain or cough medicines; suitability requires clinician review. Product imagery shows a format, not verified dispensed packaging; formulations and availability vary.
Discuss at a consultationA closer look
Options with context.
Evidence limitations
The clinic discusses limited evidence and the need to consider established alternatives. No generalized outcome or treatment response is promised.
Safety context
Reported side effects include vivid dreams, insomnia, headache and stomach upset. The clinician reviews risks and medication interactions in the individual context.
Care coordination
An LDN discussion is separate from hormone, metabolic or peptide treatment decisions. It does not establish a combined regimen.
Costs, stated clearlyA consultation.
A consultation.
A separate care decision.
Self-pay. No insurance billing. HSA/FSA eligibility depends on the individual plan. The clinic confirms the complete cost before care begins.
View all pricingMedication and laboratory costs vary and are reviewed before treatment begins. Self-pay; no insurance billing. HSA/FSA eligibility depends on the individual plan.
Book NowBefore a conversation
A few clear answers.
Clinical context matters. These answers explain the process, not an individual recommendation.
Is compounded LDN FDA-approved?
No. Compounded low-dose preparations are not FDA-approved; the FDA does not verify their safety, effectiveness or quality.
Can LDN be combined with opioids?
No. LDN cannot be combined with opioid medicines. Medication review and clinician guidance are required.
Are benefits established for every listed concern?
No. Evidence is limited and varies by clinical indication. The appropriate recommendation may be an established alternative, further evaluation or no medication.
Separate questions. Connected evaluation.
Let’s talk
Start with a conversation.
Houston clinic. Texas telehealth.